Clinical Pharmacology & Therapeutics · 2009 · 132 citations · 32 references
MedicineMolecular GeneticsPharmacologyDrug MetabolismGenetic ToxicologyPharmacogeneticsCytochrome P450 EnzymesCytochrome P450-mediated MetabolismDrug Metabolism GeneticsInborn Errors Of MetabolismCyp2c19 Drug MetabolismCyp2c19 GenotypeCyp2d6 Drug MetabolismCytochrome P450 2D6Death CasesFatal PoisoningToxic MetabolitesUltrarapid Metabolizer Phenotype
In Sweden, about 550 individuals die every year of drug intoxication. Many of these drugs are metabolized by CYP enzymes such as CYP2D6 and CYP2C19. A lack of these enzymes, resulting in poor metabolism, can lead to adverse reactions and even to fatality. On the other hand, an ultrarapid metabolism can lead to insufficient drug plasma concentration, resulting in failure of treatment, or it can lead to high concentrations of active/toxic metabolites. The aim of this project was to study the genetic profile of individuals with regard to the presence of CYP2D6 and CYP2C19 genes, in cases of fatal intoxication (242), suicide (intoxications excluded) (262), and natural death (212). PCR, followed by pyrosequencing, was used for all the analyses. We found that, among those who died of suicide (suicide cases), there was a higher number carrying more than two active CYP2D6 genes (corresponding to the phenotype of ultrarapid metabolizer) as compared with those who died of natural causes (natural-death cases) (P = 0.007).
32
Sung Eun Sim, Carl Risinger, Eleni Aklillu et al. · Clinical Pharmacology & Therapeutics · 2006 · 729 citations
Eleni Aklillu, Irene Persson, Leif Bertilsson et al. · Journal of Pharmacology and Experimental Therapeutics · 1996 · 396 citations